These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 17204356)

  • 1. Post Launch Monitoring of food products: what can be learned from pharmacovigilance.
    van Puijenbroek EP; Hepburn PA; Herd TM; van Grootheest AC
    Regul Toxicol Pharmacol; 2007 Mar; 47(2):213-20. PubMed ID: 17204356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety monitoring of new anti-malarials in immediate post-marketing phase.
    Edwards IR
    Med Trop (Mars); 1998; 58(3 Suppl):93-6. PubMed ID: 10212911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
    Goldman SA
    Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
    [No Abstract]   [Full Text] [Related]  

  • 5. Automated support for pharmacovigilance: a proposed system.
    Bright RA; Nelson RC
    Pharmacoepidemiol Drug Saf; 2002 Mar; 11(2):121-5. PubMed ID: 11998536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system.
    Koh Y; Yap CW; Li SC
    Int J Med Inform; 2008 Jun; 77(6):421-30. PubMed ID: 17921048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Veterinary pharmacovigilance in the European context.
    Keck G
    Ann Ist Super Sanita; 1992; 28(4):425-8. PubMed ID: 1303032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Direct reporting of side effects by the patient: favourable experience in the first year].
    van Grootheest AC; Passier JL; van Puijenbroek EP
    Ned Tijdschr Geneeskd; 2005 Mar; 149(10):529-33. PubMed ID: 15782689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety evaluation of phytosterol-esters. Part 9: Results of a European post-launch monitoring programme.
    Lea LJ; Hepburn PA
    Food Chem Toxicol; 2006 Aug; 44(8):1213-22. PubMed ID: 16542769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cosmetovigilance: a French pharmacovigilance system for cosmetics developed by the French health products safety agency. A proposal for the future].
    Tissier MH; Lepagnol F
    Therapie; 2002; 57(3):273-82. PubMed ID: 12422542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The need for 'postmarketing surveillance'].
    Stricker BH; in 't Veld BA; Feenstra J
    Ned Tijdschr Geneeskd; 1999 Apr; 143(14):711-3. PubMed ID: 10347624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.
    de Langen JJ; van Puijenbroek EP
    Neth J Med; 2006 Oct; 64(9):334-8. PubMed ID: 17057271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmarketing surveillance.
    Oleen MA
    Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring risk: post marketing surveillance and signal detection.
    Dart RC
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S26-32. PubMed ID: 19748743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A model for the future conduct of pharmacovigilance.
    Waller PC; Evans SJ
    Pharmacoepidemiol Drug Saf; 2003; 12(1):17-29. PubMed ID: 12616844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacovigilance off the beaten track: herbal surveillance or pharmacovigilance of medicinal plants].
    Castot A; Djezzar S; Deleau N; Guillot B; Efthymiou ML
    Therapie; 1997; 52(2):97-103. PubMed ID: 9231502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-market surveillance of GM foods: applicability and limitations of schemes used with pharmaceuticals and some non-GM novel foods.
    Wal JM; Hepburn PA; Lea LJ; Crevel RW
    Regul Toxicol Pharmacol; 2003 Aug; 38(1):98-104. PubMed ID: 12878059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A qualitative approach to signal mining in pharmacovigilance using formal concept analysis.
    Lillo-Le Louët A; Toussaint Y; Villerd J
    Stud Health Technol Inform; 2010; 160(Pt 2):969-73. PubMed ID: 20841828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.